Wu Catherine J, Krishnamurti Lakshamanan, Kutok Jeffery L, Biernacki Melinda, Rogers Shelby, Zhang Wandi, Antin Joseph H, Ritz Jerome
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Blood. 2005 Nov 15;106(10):3639-45. doi: 10.1182/blood-2005-04-1376. Epub 2005 Aug 9.
Peripheral destruction of sickled erythrocytes is a cardinal feature of sickle cell disease (SCD). Less well established is the potential contribution of ineffective erythropoiesis to the pathophysiology of this hemoglobinopathy. Since patients with SCD frequently develop mixed hematopoietic chimerism after allogeneic nonmyeloablative stem cell transplantation, we used this opportunity to directly compare the differentiation and survival of SCD and donor-derived erythropoiesis in vivo. Donor and recipient erythropoiesis was compared in 4 patients with SCD and 4 without SCD who developed stable mixed hematopoietic chimerism following transplant. Molecular analysis of chimerism in peripheral blood and bone marrow demonstrated higher expression of donor-derived beta-globin RNA relative to the level of donor-derived genomic DNA in patients with SCD. Analysis of chimerism in immature (glycophorin A-positive [GYPA(+)], CD71(hi)) and mature (GYPA(+), CD71(neg)) erythroblasts confirmed the intramedullary loss of SS erythroblasts with progressive maturation. In patients with SCD, relative enrichment of donor erythroid precursors began to appear at the onset of hemoglobinization. Ineffective erythropoiesis of homozygous hemoglobin S (SS) progenitors thus provides a maturation advantage for homozygous hemoglobin A (AA) or heterozygous hemoglobin S/hemoglobin A (SA) donor erythroid precursor cells that results in greater donor contribution to overall erythropoiesis following stem-cell transplantation and improvement of clinical disease.
镰状红细胞的外周破坏是镰状细胞病(SCD)的主要特征。而无效红细胞生成对这种血红蛋白病病理生理学的潜在贡献尚未完全明确。由于SCD患者在异基因非清髓性干细胞移植后常出现混合造血嵌合体,我们利用这一机会直接比较了SCD和供体来源的红细胞生成在体内的分化和存活情况。在4例SCD患者和4例非SCD患者中比较了供体和受体的红细胞生成情况,这些患者在移植后均形成了稳定的混合造血嵌合体。对外周血和骨髓嵌合体的分子分析表明,与非SCD患者相比,SCD患者中供体来源的β-珠蛋白RNA表达相对于供体来源的基因组DNA水平更高。对未成熟(血型糖蛋白A阳性[GYPA(+)]、CD71高表达)和成红细胞(GYPA(+)、CD71阴性)嵌合体的分析证实,SS成红细胞在骨髓内随着成熟而逐渐丢失。在SCD患者中,供体红系前体细胞的相对富集在血红蛋白化开始时就开始出现。因此,纯合血红蛋白S(SS)祖细胞的无效红细胞生成,为纯合血红蛋白A(AA)或杂合血红蛋白S/血红蛋白A(SA)供体红系前体细胞提供了成熟优势,这导致干细胞移植后供体对总体红细胞生成的贡献更大,并改善了临床疾病。